[HTML][HTML] Programming CAR-T cells to kill cancer
T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …
antigens have led to high complete response rates in patients with haematologic …
[HTML][HTML] CAR-T cell potency: from structural elements to vector backbone components
M Mazinani, F Rahbarizadeh - Biomarker research, 2022 - Springer
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved remarkable success in some …
engineered to recognize and kill cancer cells, has achieved remarkable success in some …
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
CR Funk, S Wang, KZ Chen, A Waller… - Blood, The Journal …, 2022 - ashpublications.org
Current limitations in using chimeric antigen receptor T (CART) cells to treat patients with
hematological cancers include limited expansion and persistence in vivo that contribute to …
hematological cancers include limited expansion and persistence in vivo that contribute to …
[HTML][HTML] Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
LC Fleischer, HT Spencer, SS Raikar - Journal of hematology & oncology, 2019 - Springer
Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell
malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for …
malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for …
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
CT Petersen, M Hassan, AB Morris, J Jeffery… - Blood …, 2018 - ashpublications.org
Adoptive therapy with ex vivo–expanded genetically modified antigen-specific T cells can
induce remissions in patients with relapsed/refractory cancer. The clinical success of this …
induce remissions in patients with relapsed/refractory cancer. The clinical success of this …
Evolution of alternative adaptive immune systems in vertebrates
T Boehm, M Hirano, SJ Holland, S Das… - Annual review of …, 2018 - annualreviews.org
Adaptive immunity in jawless fishes is based on antigen recognition by three types of
variable lymphocyte receptors (VLRs) composed of variable leucine-rich repeats, which are …
variable lymphocyte receptors (VLRs) composed of variable leucine-rich repeats, which are …
[HTML][HTML] CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization
S Qiu, J Chen, T Wu, L Li, G Wang, H Wu, X Song… - Cell Research, 2024 - nature.com
Dear Editor, Tonic signaling of chimeric antigen receptors (CARs) plays a pivotal role in
governing CAR-T cell fitness: inefficient tonic signaling results in poor CAR-T persistence …
governing CAR-T cell fitness: inefficient tonic signaling results in poor CAR-T persistence …
Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited …
Relapsed T-cell malignancies have poor outcomes when treated with chemotherapy, but
survival after allogeneic bone marrow transplantation (BMT) approaches 50%. A limitation to …
survival after allogeneic bone marrow transplantation (BMT) approaches 50%. A limitation to …
[HTML][HTML] Development of smart anti-glycan reagents using immunized lampreys
TR McKitrick, CK Goth, CS Rosenberg… - Communications …, 2020 - nature.com
Studies on the expression of cellular glycans are limited by a lack of sensitive tools that can
discriminate specific structural features. Here we describe the development of a robust …
discriminate specific structural features. Here we describe the development of a robust …
[HTML][HTML] Non-signaling chimeric antigen receptors enhance antigen-directed killing by γδ T cells in contrast to αβ T cells
LC Fleischer, SA Becker, RE Ryan, A Fedanov… - Molecular Therapy …, 2020 - cell.com
Chimeric antigen receptor (CAR)-modified T cells have demonstrated efficacy against B cell
leukemias/lymphomas. However, redirecting CAR T cells to malignant T cells is more …
leukemias/lymphomas. However, redirecting CAR T cells to malignant T cells is more …